C3 Jian, Inc., a private company focused on reengineering the human microbiome to deliver novel health-care products, announced that its team of researchers, together with collaborators from UCLA, the University of Washington, and the Craig Venter Institute have published a ground-breaking manuscript highlighting the targeted removal of bacteria and its impact on the remaining ecology of the microbiome. The manuscript, published June 1, 2015, by the Proceedings of the National Academy of Sciences (PNAS) describes the mechanism by which C3 Jian’s product candidate targets the specific elimination of Streptococcus mutans (S. mutans) that may alter the oral microbiome to provide long-lasting therapeutic benefits.

(Visited 15 times, 1 visits today)